The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders

References

• Vyvanse [package insert]. Shire US Inc., Wayne, PA, USA. 2013
   Google Scholar
• Positive response from European regulatory procedure supports approval of Elvanse® (lisdexamfetamine dimesylate) for ADHD. Available from: www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=684
   Google Scholar
• Summary of product characteristics. Available from: www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1369116790036.pdf
   Google Scholar
• Public assessment report decentralised procedure. Elvanse 30 mg, 50 mg and 70 mg capsules hard. Lisdexamfetamine dimesylate. UK/H/3326/001-03/DC. Available from: www.mhra.gov.uk/home/groups/par/documents/websiteresources/con261790.pdf
   Google Scholar
• Jana S, Mandlekar S, Marathe P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr Med Chem 2010;17:3874-908
   PubMed Web of Science ®Google Scholar
• Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmacol Res 2013;65:1-14
   Google Scholar
• Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present a pharmacological and clinical perspective. J Psychopharmacol 2013;27:479-96
   PubMed Web of Science ®Google Scholar
• Heal DJ, Smith SL, Findling RL. ADHD: current and future therapeutics. Curr Top Behav Neurosci 2012;9:361-90
   PubMedGoogle Scholar
• Childress AC, Sallee FR. The use of lisdexamfetamine dimesylate for the treatment of ADHD. Exp Rev Neurother 2012;12:13-26
   PubMed Web of Science ®Google Scholar
• Rowley HL, Kulkarni R, Gosden J, et al. Lisdexamfetamine and immediate-release d-amfetamine – differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacology 2012;63:1064-74
   PubMed Web of Science ®Google Scholar
• Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:179-203
   PubMed Web of Science ®Google Scholar
• Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med 2009;121:11-19
   PubMed Web of Science ®Google Scholar
• Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48:293-302
   PubMed Web of Science ®Google Scholar
• Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010;6:317-27
   PubMed Web of Science ®Google Scholar
• Pennick M. Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell donors. J Drug Assessment 2013;2:17-20
   PubMedGoogle Scholar
• Ermer JC, Haffel MB, Doll WJ, et al. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy volunteers. Drug Metab Dispos 2012;40:290-7
   PubMedGoogle Scholar
• Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-6
   PubMed Web of Science ®Google Scholar
• Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008;24:33-40
   PubMed Web of Science ®Google Scholar
• Ermer JC, Dennis K, Haffey MB, et al. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Invest 2011;31:357-70
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009;23:410-18
   PubMed Web of Science ®Google Scholar
• Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010;50:1001-10
   PubMed Web of Science ®Google Scholar
• Boellner SW, Stark JG, Krishnan S, Zhang Y. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clin Ther 2010;32:252-64
   PubMed Web of Science ®Google Scholar
• Madaan V, Kolli V, Bestha DP, Shah MJ. Update on optimal use of lisdexamfetamine in the treatment of ADHD. Neuropsychiatr Dis Treat 2013;9:977-83
   PubMed Web of Science ®Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010;11:516-25
   PubMed Web of Science ®Google Scholar
• Ball SE, Ahern D, Scatina J, et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997;43:619-26
   PubMed Web of Science ®Google Scholar
• Ermer J, Haffey MB, Richards C, et al. Open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. Clin Drug Invest 2013;33(4):243-54
   PubMedGoogle Scholar
• L-lysine. Monograph. Altern Med Rev 2007;12:169-72
   PubMedGoogle Scholar
• Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Invest 2008;28:745-55
   PubMed Web of Science ®Google Scholar
• Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med 2009;121:11-19
   PubMed Web of Science ®Google Scholar
• Hodgkins P, Shaw M, McCarthy S, Sallee FR. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter. CNS Drugs 2012;26:245-68
   PubMed Web of Science ®Google Scholar
• Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol 2012;86:1167-231
   PubMed Web of Science ®Google Scholar
• Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007;47:681-98
   PubMed Web of Science ®Google Scholar
• Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 2010;33:821-42
   PubMed Web of Science ®Google Scholar
• Roesch B, Corcoran ME, Fetterold J, et al. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs 2013;13:119-28
   Google Scholar
• Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology 2013;39(6):1388-98
   PubMedGoogle Scholar
• Trivedi MH, Cutler AJ, Richards C, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry 2013;74:802-9
   PubMed Web of Science ®Google Scholar
• Morrow SA, Smerbeck A, Patrick K, et al. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. J Neurol 2013;260:489-97
   PubMed Web of Science ®Google Scholar
• Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007;20:386-92
   PubMed Web of Science ®Google Scholar
• Döpfner M, Breuer D, Wille N, et al. BELLA study group. How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? parent-based prevalence rates in a national sample—results of the BELLA study. Eur Child Adolesc Psychiatry 2008;17(Suppl 1):59-70
   PubMedGoogle Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
   PubMed Web of Science ®Google Scholar
• Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr 2007;166:117-23
   PubMed Web of Science ®Google Scholar
• Amiri S, Shafiee-Kandjani AR, Fakhari A, et al. Psychiatric comorbidities in ADHD children: an Iranian study among primary school students. Arch Iran Med 2013;16:513-17
   PubMedGoogle Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Gillberg C, Gillberg IC, Rasmussen P, et al. Co-existing disorders in ADHD–implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2008;13:80-90
   Google Scholar
• van de Glind G, Konstenius M, Koeter MW, et al. Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug Alcohol Depend 2014;134:158-66
   PubMed Web of Science ®Google Scholar
• Voeller KK. Attention-deficit hyperactivity disorder (ADHD). J Child Neurol 2004;19:798-814
   PubMed Web of Science ®Google Scholar
• Emond V, Joyal C, Poissant H. Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD). Encephale 2009;35:107-14
   PubMed Web of Science ®Google Scholar
• Cubillo A, Halari R, Ecker C, et al. Reduced activation and inter-regional functional connectivity of fronto-striatal networks in adults with childhood Attention-Deficit Hyperactivity Disorder (ADHD) and persisting symptoms during tasks of motor inhibition and cognitive switching. J Psychiatr Res 2010;44:629-39
   PubMed Web of Science ®Google Scholar
• Fone KC, Nutt DJ. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 2005;5:87-93
   PubMedGoogle Scholar
• Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 2009;29:656-79
   PubMed Web of Science ®Google Scholar
• Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23(Suppl 1):21-31
   PubMed Web of Science ®Google Scholar
• Steer C, Froelich J, Soutullo CA, et al. Lisdexamfetamine dimesylate. A new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs 2012;26:691-705
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014;156:1-7
   PubMed Web of Science ®Google Scholar
• Lasser RA, Dirks B, Nasrallah H, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology 2013;38:2140-9
   PubMedGoogle Scholar
• Mattingly G. Liusdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adult. CNS Spectr 2010;15:315-25
   PubMedGoogle Scholar
• Faraone SV. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Atten Disord 2012;16:128-37
   PubMed Web of Science ®Google Scholar
• Wigal SB, Raja P, Shukla A. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother 2013;14:137-45
   PubMed Web of Science ®Google Scholar
• Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29:450-63
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008;13:614-20
   PubMed Web of Science ®Google Scholar
• Wigal SB, Kollins SH, Childress AC, Squires L; for the 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009;3:17
   Google Scholar
• Wigal SB, Maltas S, Crinella F, et al. Reading performance as a function of treatment with lisdexamfetamine dimesylate in elementary school children diagnosed with ADHD. J Atten Disord 2012;16:23-33
   PubMed Web of Science ®Google Scholar
• Jain J, Babcock T, Burtea T, et al. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child Adolesc Psychiatry Ment Health 2011;5:35
   PubMedGoogle Scholar
• Findling RL, Adeyi B, Dirks B, et al. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate. J Child Adolesc Psychopharmacol 2013;23:28-35
   PubMed Web of Science ®Google Scholar
• Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol 2009;19:64-662
   Google Scholar
• Coghill D, Banaschewski T, Lecendreux M, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 2013;23:1208-18
   PubMed Web of Science ®Google Scholar
• Coghill D, Banaschewski T, Lecendreux M, et al. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized controlled trial. Eur Child Adolesc Psychiatry 2013;23(2):61-8
   PubMedGoogle Scholar
• Banaschewski T, Soutullo C, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs 2013;27:829-40
   PubMed Web of Science ®Google Scholar
• Soutullo C, Banaschewski T, Lecendreux M, et al. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 2013;27:743-51
   PubMed Web of Science ®Google Scholar
• Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 2013;27:1081-92
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50:395-405
   PubMed Web of Science ®Google Scholar
• Findling RL, Cutler AJ, Saylor K, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2013;23:11-21
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-73
   PubMed Web of Science ®Google Scholar
• Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 2009;14:573-85
   PubMed Web of Science ®Google Scholar
• Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 2010;6:4
   PubMedGoogle Scholar
• Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry 2012;73:977-83
   PubMed Web of Science ®Google Scholar
• Mattingly G, Weisler R, Dirks B, et al. Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate. Innov Clin Neurosci 2012;9:22-30
   PubMedGoogle Scholar
• Biederman J, Fried R, Hammerness P, et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res 2012;46:484-91
   PubMed Web of Science ®Google Scholar
• Adler LA, Lynch LR, Shaw DM, et al. Effectiveness and duration of effect of open-label lisdexamfetamine dimesylate in adults with ADHD. J Atten Disord 2013. [Epub ahead of print]
   Google Scholar
• Adler LA, Dirks B, Deas PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013;74:694-702
   PubMed Web of Science ®Google Scholar
• Adler LA, Dirks B, Deas P, et al. Self-reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study. BMC Psychiatry 2013;13:253
   PubMedGoogle Scholar
• Kollins SH, Youcha S, Lasser R, Thase ME. Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. Innov Clin Neurosci 2011;8:28-32
   PubMedGoogle Scholar
• Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010;122:184-91
   PubMed Web of Science ®Google Scholar
• Setyawan J, Guérin A, Hodgkins P, et al. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. J Med Econ 2013;16:1275-89
   PubMedGoogle Scholar
• Setyawan J, Hodgkins P, Guérin A, et al. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ 2013;16:962-75
   PubMedGoogle Scholar
• Setyawan J, Hodgkins P, Guérin A, et al. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults. J Med Econ 2013;16:1203-15
   PubMedGoogle Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23:419-27
   PubMed Web of Science ®Google Scholar
• Cassidy TA, McNaughton EC, Varughese S, et al. Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: early findings from the navippro surveillance system. J Atten Disord 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Sembower MA, Ertischek MD, Buchholtz C, et al. Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. J Addict Dis 2013;32:26-38
   PubMed Web of Science ®Google Scholar
• Sweeney CT, Sembower MA, Ertischek MD, et al. Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse. Addict Dis 2013;32:1-10
   Google Scholar
• National Forensic Laboratory Information System. Special report: ADD/ADHD Stimulants in NFLIS, 2007-2011. US Drug Enforcement Administration. 2012. Available from: www.deadiversion.usdoj.gov/nflis/spec_rpt_adhd_2012.pdf [Last accessed 21 May 21014]
   Google Scholar
• Schaeffer T. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol 2012;8:400-7
   PubMedGoogle Scholar
• US. National Institutes of Health. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/results?term=lisdexamfetamine+dimesylate&Search=Search [Last accessed 9 January 2014]
   Google Scholar
• EU. Clinical trial register. Available from: www.clinicaltrialsregister.eu/ctr-search/search?query=lisdexamfetamine+dimesylate [Last accessed 9 January 2014]
   Google Scholar
• Shire. Positive top-line results shown for Vyvanse(R) (lisdexamfetamine dimesylate) capsules (CII) in adults with binge eating disorder. Available from: www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=877 [Last accessed 21 May 2014]
   Google Scholar
• Shire reports top-line results from two phase 3 studies for Vyvanse® (lisdexamfetamine dimesylate) capsules (CII) as an adjunctive treatment for adults with major depressive disorder. Available from: www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=921 [Last accessed 21 May 2014]
   Google Scholar